Apr. 18 at 10:14 AM
$BCYC 'BT5528 + nivo demonstrated a generally well-tolerated safety profile across doses, with no new safety signals, in contrast to prior attempts to target EphA2, with no PK drug-drug interactions. Preliminary anti-tumor activity was demonstrated in pts with mUC at a dose of BT5528 6.5 mg/m2 once every 2 wks + nivo 480 mg once every 4 wks, especially in MMAE-naive pts with EphA2+ tumors'.
https://aacrjournals.org/cancerres/article/86/8_Supplement/CT063/783018/Abstract-CT063-An-EphA2-targeting-Bicycle-Drug?searchresult=1
